Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2026-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text is a formal notice titled “정기주주총회 결과” detailing the results of motions voted on at the company’s Annual General Meeting on 2026-03-26, including vote tallies for director appointments, dividend approvals, and other resolutions. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for Daihan Pharm Co., Ltd. (대한약품공업주식회사) for the 62nd fiscal year (2025). It contains comprehensive sections including company overview, business details, financial statements, management analysis, and governance information. This structure corresponds to the standard Korean Annual Report filing (10-K equivalent). FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a specific regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a simple announcement of report publication (RPA). It fits the definition of an Audit Report/Information (AR) as it provides the audit opinion and financial summary. FY 2025
2026-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daihan Pharmaceutical Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's report on business operations and financial statements (balance sheet, income statement, etc.) to be approved at the meeting. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on agenda items at the upcoming Annual General Meeting.
2026-03-06 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (equivalent to a Proxy Statement/DEF 14A) used to solicit shareholder votes for an upcoming Annual General Meeting. It includes details on the meeting date, agenda items (such as approval of financial statements), and proxy solicitation procedures. While it contains financial statements, these are provided as part of the proxy materials for shareholder review prior to the meeting, not as a standalone annual report.
2026-03-06 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Daehan Pharmaceutical. It details the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-02-25 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.